Travere Therapeutics (TVTX) Cash from Financing Activities (2013 - 2026)
Travere Therapeutics posted quarterly Cash from Financing Activities of $4.2 million for Q1 2026, up 13.07% year-on-year from $3.7 million in Q1 2025, and down 84.24% on a QoQ basis from $26.7 million in Q4 2025.
Travere Therapeutics (TVTX) has 14 years of Cash from Financing Activities data on file, last reported at $4.2 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 13.07% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at -$33.0 million (down 122.96% YoY), and the FY2025 full-year result was -$33.5 million, down 124.0% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $4.2 million, down from $26.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $217.0 million in Q1 2023 and bottomed at -$65.3 million in Q3 2025.
- The 5-year median for Cash from Financing Activities is $1.5 million (2025), against an average of $26.4 million.
- The widest annual swing landed in 2024, when Cash from Financing Activities jumped 112092.74%; it then plunged 142141.3% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $1.2 million in 2022, then sank by 89.26% to $124000.0 in 2023, then surged by 112092.74% to $139.1 million in 2024, then plunged by 80.82% to $26.7 million in 2025, then tumbled by 84.24% to $4.2 million in 2026.
- The last three Cash from Financing Activities figures came in at $4.2 million (Q1 2026), $26.7 million (Q4 2025), and -$65.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Travere Therapeutics | 4.14 Bn | 4.06 Bn | 102.38 Mn | 4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.20 Mn |
| Mar 31, 2026 | 4.20 Mn |
| Dec 31, 2025 | 26.68 Mn |
| Dec 31, 2025 | 26.68 Mn |
| Sep 30, 2025 | -65.34 Mn |
| Sep 30, 2025 | -65.34 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 3.72 Mn |
| Mar 31, 2025 | 3.72 Mn |
| Dec 31, 2024 | 139.12 Mn |
| Dec 31, 2024 | 139.12 Mn |
| Sep 30, 2024 | 46,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 782,000.00 |
| Jun 30, 2024 | 782,000.00 |
| Mar 31, 2024 | -525,000.00 |
| Mar 31, 2024 | -525,000.00 |
| Dec 31, 2023 | 124,000.00 |
| Dec 31, 2023 | 124,000.00 |
| Sep 30, 2023 | -1.50 Mn |
| Sep 30, 2023 | -1.50 Mn |
| Jun 30, 2023 | 3.13 Mn |
| Jun 30, 2023 | 3.13 Mn |
| Mar 31, 2023 | 217.00 Mn |
| Mar 31, 2023 | 217.00 Mn |
| Dec 31, 2022 | 1.16 Mn |
| Dec 31, 2022 | 1.16 Mn |
| Sep 30, 2022 | 4.15 Mn |
| Sep 30, 2022 | 4.15 Mn |
| Jun 30, 2022 | 831,000.00 |
| Jun 30, 2022 | 831,000.00 |
| Mar 31, 2022 | 113.91 Mn |
| Mar 31, 2022 | 113.91 Mn |
| Dec 31, 2021 | 39.32 Mn |
| Dec 31, 2021 | 39.32 Mn |
| Sep 30, 2021 | 2.41 Mn |
| Sep 30, 2021 | 2.41 Mn |
| Jun 30, 2021 | 303,000.00 |
| Jun 30, 2021 | 303,000.00 |
| Mar 31, 2021 | 195.75 Mn |
| Mar 31, 2021 | 195.75 Mn |
| Dec 31, 2020 | 25.04 Mn |
| Dec 31, 2020 | 25.04 Mn |
| Sep 30, 2020 | -348,000.00 |
| Sep 30, 2020 | -348,000.00 |
| Jun 30, 2020 | 108.80 Mn |
| Jun 30, 2020 | 108.80 Mn |
| Mar 31, 2020 | -5.77 Mn |
| Mar 31, 2020 | -5.77 Mn |
| Dec 31, 2019 | 95,000.00 |
| Dec 31, 2019 | 95,000.00 |
| Sep 30, 2019 | -738,000.00 |
| Sep 30, 2019 | -738,000.00 |
| Jun 30, 2019 | -324,000.00 |
| Jun 30, 2019 | -324,000.00 |
| Mar 31, 2019 | -1.11 Mn |
| Mar 31, 2019 | -1.11 Mn |
| Dec 31, 2018 | 525,000.00 |
| Dec 31, 2018 | 525,000.00 |
| Sep 30, 2018 | 230.96 Mn |
| Sep 30, 2018 | 230.96 Mn |
| Jun 30, 2018 | 3.09 Mn |
| Jun 30, 2018 | 3.09 Mn |
| Mar 31, 2018 | -2.70 Mn |
| Mar 31, 2018 | -2.70 Mn |
| Dec 31, 2017 | 1.36 Mn |
| Dec 31, 2017 | 1.36 Mn |
| Sep 30, 2017 | 5.84 Mn |
| Sep 30, 2017 | 5.84 Mn |
| Jun 30, 2017 | -1.90 Mn |
| Jun 30, 2017 | -1.90 Mn |
| Mar 31, 2017 | 146,000.00 |
| Mar 31, 2017 | 146,000.00 |
| Dec 31, 2016 | -5.04 Mn |
| Dec 31, 2016 | -5.04 Mn |
| Sep 30, 2016 | 4.04 Mn |
| Sep 30, 2016 | 4.04 Mn |
| Jun 30, 2016 | -1.92 Mn |
| Jun 30, 2016 | -1.92 Mn |
| Mar 31, 2016 | -926,000.00 |
| Mar 31, 2016 | -926,000.00 |
| Dec 31, 2015 | 1.23 Mn |
| Dec 31, 2015 | 1.23 Mn |
| Sep 30, 2015 | -40.11 Mn |
| Sep 30, 2015 | -40.11 Mn |
| Jun 30, 2015 | 1.11 Mn |
| Jun 30, 2015 | 1.11 Mn |
| Mar 31, 2015 | 139.38 Mn |
| Mar 31, 2015 | 139.38 Mn |
| Dec 31, 2014 | -533,000.00 |
| Dec 31, 2014 | -533,000.00 |
| Sep 30, 2014 | 3.55 Mn |
| Sep 30, 2014 | 3.55 Mn |
| Jun 30, 2014 | 53.69 Mn |
| Jun 30, 2014 | 53.69 Mn |
| Mar 31, 2014 | 38.62 Mn |
| Mar 31, 2014 | 38.62 Mn |
| Dec 31, 2013 | -280,295.00 |
| Dec 31, 2013 | -280,295.00 |
| Mar 31, 2013 | 8.38 Mn |
| Mar 31, 2013 | 8.38 Mn |